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Management of ovarian cancer risk

Prophylactic oophorectomy
The lifetime risk of ovarian cancer for women with BRCA1 mutations is estimated at 40-50% (Ford et al., 1994; Antoniou et al., 2003; King et al., 2003) and in those with BRCA2 mutations, at 10-20% (1999; Antoniou et al., 2003; King et al., 2003) . We and others have shown conclusively that prophylactic oophorectomy (PO) in women with BRCA1/2 mutations reduces the risk of ovarian cancer by approximately 90% (Kauff et al., 2002; Rebbeck et al., 2002; Rutter et al., 2003; Domchek et al., 2006) . Data with short-term follow-up also suggests that oophorectomy is associated with an improvement in breast cancer-specific survival, ovarian cancer-specific survival and overall survival (Domchek et al., 2006) (Figure 1) . Table 1 reports the details of studies examining PO in BRCA1/2 mutation carriers. Rebbeck et al. (2002) examined 551 women from 11 centers in North America and Europe who either did (n ¼ 259) or did not (n ¼ 292) undergo PO, with a mean follow-up of over 8 years in each group. Eight PO subjects (3.1%) were diagnosed with ovarian cancer or primary peritoneal cancer at or following PO compared with 58 controls (19.9%). Six of the eight PO subjects diagnosed with ovarian cancer were diagnosed at the time of PO, all of which were stage I. After excluding these six cases, only two women (both with BRCA1 mutations) who underwent PO subsequently developed primary peritoneal cancer. Compared with women who did not undergo PO, the occurrence of post-PO ovarian cancer corresponded to a hazard ratio (HR) of 0.04 (95% confidence interval (CI): 0.01-0.16). In addition to this striking reduction in the risk of ovarian cancer, an approximately 50% breast cancer risk reduction after PO was also observed (HR ¼ 0.47; 95% CI: 0.29-0.77). In an another study with similar results, Kauff et al. (2002) identified 170 women with BRCA1/2 mutations who had not previously undergone PO, who then chose to either undergo ovarian cancer surveillance or undergo PO. During a mean follow-up of 24.2 months, ovarian cancer or primary peritoneal carcinoma was diagnosed in one of 98 women who chose to undergo PO compared to five ovarian or peritoneal cancers in the 72 women who chose surveillance. This risk reduction corresponded to a HR of 0.15 (95% CI: 0.02-1.31).
Finally, Domchek et al. (2006) examined the effect of oophorectomy on mortality in BRCA1/2 mutation carriers. In the primary analysis, 426 women unaffected with either breast or ovarian cancer before their oophorectomy and prospectively followed were age-matched to women who did not undergo PO and who were unaffected with cancer at the time that their match underwent PO. At a median follow-up of 2-3 years, PO led to a risk reduction for breast cancer (HR 0.36, ) and ovarian cancer (HR 0.11, 0.03-0.47) consistent with prior reports. In addition, a reduction in breast cancer-specific mortality (HR 0.10, 0.02-0.71), ovarian cancer-specific mortality (HR 0.05, 0.01-0.46) and overall mortality (HR 0.24, 0.08-0.71) were also seen. Median follow-up time in this study is short, and the sample size still relatively small. Despite the limitations, these data provide further evidence that PO in BRCA1/2 mutation carriers is of benefit. No randomized clinical trials have been undertaken to assess the efficacy of PO on ovarian cancer risk reduction in BRCA1/2 mutation carriers, but given the current knowledge of ovarian cancer risk reduction conferred by PO in these women, it is unlikely that such a trial would be acceptable to patients, nor would it be ethical to randomize BRCA1/2 mutation carriers to an arm of a trial that did not include PO given the absence of effective screening for ovarian cancer.
Primary peritoneal cancer and fallopian tube carcinoma
Despite the large magnitude of ovarian cancer risk reduction, PO does not completely eliminate risk. Primary peritoneal cancers have been reported in women with BRCA1/2 mutations following PO with an estimated frequency of 2-4%, and occur more frequently in BRCA1 compared to BRCA2 carriers (Piver et al., 1993; Kauff et al., 2002; Rebbeck et al., 2002; Casey et al., 2005) . Primary peritoneal cancer may occur either owing to an occult ovarian cancer focus or from carcinoma arising de novo in peritoneal mesothelium. Occult ovarian and fallopian tube carcinomas have been found at the time of PO in 2-10% of BRCA1/2 mutation carriers (Salazar et al., 1996; Lu et al., 2000; Colgan et al., 2001; McEwen et al., 2004; Powell et al., 2005) . The role of peritoneal washings at this time is unclear (Colgan et al., 2002; Powell et al., 2005) . Eitan et al. (2006) have recently reported that in 24% of BRCA1/2 carriers undergoing PO, mesothelial atypia was identified. At a median follow-up time of 20 months, none of these patients have developed peritoneal carcinoma.
Cancers of the fallopian tube, although very rare in the general population, also represent a part of the hereditary breast/ovarian cancer syndrome associated with BRCA1/2 mutations (Aziz et al., 2001; Carcangiu et al., 2004) with an estimated relative risk (RR) of greater than 100, and a lifetime risk of 3% (95% CI: 1.3-4.7) (Brose et al., 2002) . These observations support the recommendation that a thorough pathologic examination with serial sectioning of the ovaries and fallopian tubes removed by PO should be undertaken to confirm the absence of tumor at the time of surgery. Therefore, although the timing of this procedure (the need to wait until child-bearing is complete), the induction of surgical menopause, and the small residual risk of primary peritoneal cancer following oophorectomy are important considerations, oophorectomy is the single most important intervention available to BRCA1/2 mutation carriers -particularly as no effective ovarian cancer screening currently exists.
Chemoprevention of ovarian cancer
The use of oral contraceptive pills (OCP) appears to decrease the risk of ovarian cancer by up to 50% in BRCA1 and BRCA2 carriers, although one report did not find this effect (Narod et al., 1998; Modan et al., 2001; Whittemore et al., 2004) . Data are inconsistent regarding the effect of OCP on breast cancer risk. In a large retrospective case-controlled study, Narod et al. (2002) reported a modest increase in OCP-associated breast cancer risk in BRCA1 carriers (odds ratio (OR) 1.20, 1.02-1.40), particularly in those who used OCP before 1975, used OCP whereas under age 30, or used for more than 5 years. Notably, of the cases that used OCP in this study, more than 50% initiated OCP use before 1975, when the estrogen content of OCP was substantially higher than current formulations. However, a large multinational case-control study including 1156 breast cancer cases diagnosed under age 40 (of which 47 were BRCA1 carriers and 35 BRCA2 carriers) as well as 815 controls, did not demonstrate an increased risk of OCPassociated breast cancer (Milne et al., 2005) . In fact, a decrease in breast cancer risk was seen in BRCA1 carriers using OCP for >12 months (OR 0.22, 0.10-0.49). Use before 1975 was less common in this study, although this factor was associated with an excess risk of breast cancer in non-carriers, a consistent finding across both carrier and non-carrier studies. Given the excess mortality associated with ovarian cancer compared with breast cancer, a reasonable risk reduction strategy is OCP use before child bearing, and oophorectomy once child bearing is complete (optimally before age 40).
Breast cancer risk reduction via oophorectomy
Multiple groups have now shown that oophorectomy also reduces the risk of breast cancer by 50% or more (Rebbeck et al., 1999 (Rebbeck et al., , 2000 Kauff et al., 2002; (Table 1) . Indeed, as demonstrated by Kramer et al. (2005) the significant effect of oophorectomy on breast cancer risk may be one of the several reasons for the variability in penetrance estimates for breast cancer across studies. The reduction in breast cancer risk appears greatest when oophorectomy is performed before age 40 and its protective effect appears evident at least 15 years following surgery (Eisen et al., 2005) . Relative effects in BRCA1 and BRCA2 carriers remains an area of investigation, but all studies have consistently shown effects on breast cancer risk reduction. Despite the multitude of benefits associated with oophorectomy, some women delay or forego oophorectomy owing to fear of symptoms related to surgical menopause. We have recently demonstrated that short-term hormone replacement therapy (HRT) after oophorectomy in premenopausal women with no prior history of breast cancer does not impact breast cancer risk (Rebbeck et al., 2005) . Specifically, women undergoing oophorectomy had a HR of 0.40 (0.18-0.92) for the development of breast cancer. This same protective effect of oophorectomy was observed in women undergoing oophorectomy who had chosen to take HRT (0.37, 0.14-0.96) (Rebbeck et al., 2005) . Therefore, women should not forsake the benefits of oophorectomy owing to concerns of the effects of short-term HRT. Further studies are underway to determine whether timing, type (estrogen only vs estrogen plus progesterone) or duration of HRT have significant effects in this setting.
Is there a role for hysterectomy? Women who carry BRCA1/2 mutations should weigh the risks and benefits of total abdominal hysterectomy (TAH) at the time of PO based on their personal medical history and with the following four considerations: (1) impact on HRT decisions; (2) uterine and cervical cancer risk; (3) impact on decisions regarding tamoxifen; (4) fallopian tube carcinoma risk.
First, use of unopposed estrogen in the absence of hysterectomy is associated with an increased risk of endometrial cancer (RR ¼ 2.3, 95% CI: 2.1-2.5) (Grady et al., 1995; Beral et al., 2005) , thus TAH allows women who are unaffected by breast cancer to use unopposed estrogen replacement therapy rather than combined estrogen plus progesterone replacement therapy. Recent data from the Women's Health Initiative (WHI) demonstrated a significantly increased risk of breast cancer among postmenopausal women who took estrogen and progesterone (HR ¼ 1.26, 95% CI: 1.00-1.59) (Rossouw et al., 2002) , but not among women who took estrogen alone (HR ¼ 0.77, 95% CI: 0.59-1.01) (Anderson et al., 2004) . This difference is also supported by the results of the Million Women Study, which found a twofold increase in breast cancer risk for users of estrogen and progesterone (RR ¼ 2.00, 95% CI: 1.89-2.12) but a significantly lower risk for users of estrogen alone (RR ¼ 1.30, 95% CI: 1.21-1.40) (Beral, 2003) . The effect of unopposed estrogen vs combined estrogen and progesterone has not been well characterized in BRCA1/2 mutation carriers, but based on the risk of estrogen and progesterone in the Million Women Study, and the difference in the effect of estrogen alone compared to estrogen and progesterone in the WHI, the addition of progesterone remains a concern. Therefore, undergoing a TAH at the time of PO allows the use of estrogen alone for HRT that minimizes potential breast cancer risk and eliminates the endometrial cancer risk associated with unopposed estrogen exposure.
Second, a number of reports suggest there is an increased uterine and possibly cervical cancer risk in BRCA1/2 mutation carriers (uterine cancer RR ¼ 2.65, 95% CI: 1.69-4.16; cervical cancer RR ¼ 3.72, 95% CI: 2.26-6.10) (Thompson and Easton, 2002; Lavie et al., 2004) . Even though early detection of these cancers is often possible, women already planning to undergo PO may wish to eliminate uterine and cervical cancer risks by undergoing TAH at the time of their PO.
Third, tamoxifen has been shown to decrease the risk of contralateral breast cancer in BRCA1/2 mutation carriers (OR ¼ 0.50, 95% CI: 0.28-0.89) (Gronwald et al., 2006) , as will be discussed further below. Therefore, tamoxifen use for prevention of breast cancer is a consideration for BRCA1/2 mutation carriers who have completed HRT or who are not candidates for HRT. Thus eliminating the increased uterine cancer risk associated with tamoxifen (Fisher et al., 1998; Fisher et al., 2005) is an additional consideration for women contemplating TAH.
Fourth, as noted above, there is an excess risk of fallopian tube carcinoma in BRCA1/2 mutation carriers compared to the general population with an estimated RR of over 100 (Brose et al., 2002) . Because a remnant of the fallopian tube is left in the uterine wall at the time of PO without TAH, there is a theoretical benefit in considering TAH. The absolute lifetime risk for the development of fallopian tube cancer in mutation carriers is small (estimated at 3%) and there is currently very little information about the occurrence of fallopian tube cancer among women who have undergone PO without TAH, however, the possibility that residual fallopian tube tissue may make some contribution to primary peritoneal cancer risk after PO cannot be discounted.
If women consider having TAH in addition to PO, the added risk and recovery time from TAH should be considered. PO is an acceptable option in part because surgical risks and recovery time are outweighed by the benefit of a marked breast and ovarian cancer risk reduction. However, estimating risk benefit ratio for TAH in addition to PO is more complex, both owing to the small absolute advantages of TAH and the potential for higher morbidity associated with this procedure. All of these elements must be factored into the patient's decision about the surgical approach to cancer risk reduction. Women who are likely to benefit most from having a TAH at the time of PO are unaffected premenopausal women who will also be faced with decisions on HRT and future tamoxifen use. Women who are already postmenopausal or who have had breast cancer will not be considering issues of HRT and in these women the potential benefits of TAH are likely to be small.
Management of breast cancer risk
Breast cancer risk estimates for BRCA1 and BRCA2 mutation carriers vary, but cumulative evidence suggests that lifetime risk of breast cancer is 60-80% (Ford et al., 1994; Antoniou et al., 2003; King et al., 2003) , although the risk may be slighter lower in women with BRCA2 mutations. Cohort effects have been reported, with an increase in breast cancer risk seen in younger cohorts (King et al., 2003) , and as noted above, rates of oophorectomy are likely to influence penetrance data (Kramer et al., 2005) .
Prophylactic mastectomy
Despite the invasive nature of the intervention, prophylactic mastectomy (PM) is the most effective strategy available. Hartmann et al. (1999) first published data on breast cancer risk reduction after PM in women with strong family histories of breast cancer (not restricted to BRCA1/2 carriers) and demonstrated a 90% reduction in breast cancer associated with this procedure. Subsequently, several groups have confirmed that PM reduces breast cancer risk in mutation carriers by 90% (Hartmann et al., 2001; Meijers-Heijboer et al., 2001; Rebbeck et al., 2004) . However, as many women do not find this strategy acceptable for cosmetic reasons, and PO is associated with significant breast cancer risk reduction, we support chemoprevention and enhanced screening as alternative strategies. This is in contrast to our strong recommendation that PO after childbearing is complete is the only safe way to manage ovarian cancer risk in mutation carriers.
Chemoprevention
Limited data are available on the use of tamoxifen for chemoprevention of breast cancer in BRCA1/2 mutation carriers, however, the initial case-control study of mutation carriers with unilateral vs bilateral breast cancer suggested a 50% reduction in contralateral disease following at least 2 years of tamoxifen . A recent update and expansion of this study (now with 251 BRCA1/2 female mutation carriers with bilateral breast cancer, and 751 with unilateral disease) also demonstrated a significant decrease in risk of contralateral breast cancer associated with tamoxifen use in both BRCA1 (OR 0.50, 95% CI: 0.30-0.85) and BRCA2 (OR 0.42, 95% CI: 0.17-1.02) mutation carriers. This effect was seen in both premenopausal and naturally postmenopausal women. The subgroup of women with oophorectomy in this series was quite small (n ¼ 26), but no effect of tamoxifen was identified in this group (Gronwald et al., 2006) . Recent data from Pierce et al. (2006) also demonstrated a significant reduction in contralateral breast cancer risk in BRCA1/2 mutation carriers taking tamoxifen. In contrast, data from the NSABP P1 prevention trial (with eight BRCA1 and 11 BRCA2 mutation carriers) did not yield statistically significant conclusions regarding the use of tamoxifen as primary prevention in BRCA1/2 mutation carriers (King et al., 2001) . Thus, until further information is available, we believe mutation carriers should be offered tamoxifen, raloxifene or enrollment on chemoprevention trials.
Surveillance
Multiple studies have demonstrated that yearly magnetic resonance imaging (MRI) has improved sensitivity for the detection of malignancy in BRCA1/2 mutation carriers as well as other high risk women, and detects earlier stage cancers than mammography alone (Kriege et al., 2004; Warner et al., 2004; Leach et al., 2005) . In the largest reported series of known BRCA1/2 mutation carriers, Kriege et al. (2004) examined 1909 women at high risk for breast cancer (including 358 BRCA1/2 mutation carriers) with yearly mammogram and MRI, as well as semiannual clinical breast exam (CBE). The sensitivity of MRI for invasive breast cancer was 79.5%, significantly greater than that of mammogram, which had a sensitivity of 33% in this study. The specificity of MRI was 89.8% and that of mammography 95%. Similarly, Warner et al. (2004) reported on 236 mutation carriers with 457 screens performed and 22 cancers detected, of which 17 were detected by MRI. The sensitivity for MRI (77%) was significantly greater than for mammography (36%), ultrasound (US) (33%) and CBE (9%), whereas MRI has a decreased specificity (95.4%) compared to mammography (99.8%), US (96%) and CBE (99.3%). The combination of MRI, mammography and US had a sensitivity of 95%. Although the recall rate following the first MRI scan was 26%, this number declined significantly with repeat exams. Finally, Leach et al. (2005) screened 649 highrisk women (120 known mutation carriers) with MRI and mammography and demonstrated similar sensitivity (77 vs 40 vs 94% for mammography and MRI combined). In this study, the sensitivity of MRI vs mammography was particularly pronounced in the 82 BRCA1 mutation carriers (92 vs 23%). The role of US in screening BRCA1/2 mutation carriers is not clear at the current time. Warner et al. (2004) demonstrated that adding US to mammography modestly increased sensitivity, however, its inclusion triggered more biopsies than MRI after the first year of screening.
Concern has previously been raised regarding the effects of low dose ionizing radiation on BRCA1/2 mutation carriers, and the possibility that yearly mammograms might elevate breast cancer risk. Fortunately, a multicenter case-control study with 3200 BRCA1/2 mutation carriers (1600 breast cancer cases and 1600 controls, matched for BRCA1 vs BRCA2 mutation, date of birth and country of residence) has demonstrated no increased risk in breast cancer associated with mammography. The OR for the association was 1.03 (0.85-1.25) when adjusted for parity, OCP use, ethnicity and oophorectomy (Narod et al., 2006) , highlighting the potentially much greater risk of foregoing screening mammography. Although data are not yet available to determine whether alternating mammogram and MRI every 6 months or having both once yearly is more effective, owing to the high rates of interval cancers and the proposed rapid growth rate of tumors, we recommend staggering the MRI and mammogram every 6months.
Lifestyle factors
Although the effects of lifestyle interventions are relatively modest, breastfeeding, exercise and maintenance of a stable weight have all been demonstrated to decreased breast cancer risk in BRCA1/2 mutation carriers (King et al., 2003; Jernstrom et al., 2004) . Breastfeeding for longer than 1 year was associated with a decreased risk of breast cancer in BRCA1 carriers (OR 0.55, and not BRCA2 carriers (Jernstrom et al., 2004) , although a second study did not confirm this finding (Andrieu et al., 2006) . In contrast, spontaneous and therapeutic abortion is not associated with an increased risk of breast cancer in this population (Andrieu et al., 2006; Friedman et al., 2006) .
Breast cancer treatment
Local therapy Several studies have addressed the question of whether BRCA1/2 mutation carriers can be safely treated breast-conserving therapy as opposed to mastectomy. Although there is an increased risk of second primary (particularly contralateral) breast cancers, especially in the absence of oophorectomy, available data suggest that breast conserving therapy in mutation carriers is not associated with excess radiation toxicity (Pierce et al., 2000; Haffty et al., 2002; Pierce et al., 2006) . Pierce et al. (2000) recently published extended follow-up of 160 BRCA1/2 mutation carriers and 445 matched controls who underwent breast conserving therapy for breast cancer. There was no significant difference in ipsilateral breast cancer recurrence between BRCA1/2 mutation carriers and controls. With a median follow-up of 7.9 years for carriers and 6.7 years for controls, the 10-and 15-year estimates for ipsilateral recurrence were 12 and 24% in the BRCA1/2 carriers and 9 and 17% for the controls (HR 1.37, P ¼ 0.19). However, although BRCA1/2 mutation carriers who had undergone oophorectomy had no increase in ipsilateral breast cancer events, those who did not undergo oophorectomy did have an increase in ipsilateral recurrence. The rate of contralateral breast cancer was high in this study (with 10-and 15-year estimates of 26 and 39% in carriers), however, this risk was significantly reduced by both tamoxifen (HR 0.31, P ¼ 0.05) with an even more significant reduction from tamoxifen in those who did not undergo oophorectomy (HR 0.13, P ¼ 0.02). Therefore, the choice between breast conservation vs mastectomy for treatment of breast cancer in BRCA1/2 mutation carriers who are otherwise good candidates for breast conservation should center around the excess risk of a second primary breast cancer. Not surprisingly, women with a new diagnosis of breast cancer who undergo genetic testing preoperatively and are informed that they are BRCA1/2 mutation carriers, are much more likely to undergo bilateral mastectomy than women who test negative and forego testing (Schwartz et al., 2004) . However, it is important that woman be counseled on their options and their alternatives to bilateral mastectomy.
Systemic therapy
Systemic therapy for breast cancer in BRCA1/2 mutation carriers remains dictated by standard prognostic features, with no specific alterations to regimens indicated on the basis of genetic predisposition. However, BRCA1-associated tumors are more frequently of the basal phenotype (estrogen receptor, progesterone receptor and HER2/neu negative) (Lakhani et al., 1998; Lakhani et al., 2002) and for this reason adjuvant chemotherapy is frequently given. Interestingly, there is a growing body of evidence that the functional effects of loss of BRCA1 or BRCA2, as occurs in the tumors of women with heritable BRCA1 or BRCA2 mutations, may influence response to specific cancer drugs. BRCA1 and BRCA2 proteins are now known to be important for error-free DNA double-strand break repair by homologous recombination. (Venkitaraman, 2002) Therefore it has been suggested that BRCA1/2 null cancers may have enhanced sensitivity to chemotherapy that induces DNA interstrand cross-links, such as platinum agents (reviewed in (Kennedy et al., 2004) ). Data supporting this hypothesis comes in part from studies of individuals with Fanconi anemia (FA), a rare disorder manifested by progressive bone marrow failure and increased risk of malignancy owing to DNA damage repair defects arising from mutation in one of seven FA-related genes. In fact, one of the FA proteins (FANCD1) was recently shown to be BRCA2 (Howlett et al., 2002) and another FA protein (FANCD2) interacts with BRCA1 as a critical part of this DNA repair pathway (D'Andrea and Grompe, 2003) . Normal fibroblasts cultured from patients with FA are extremely sensitive to cisplatin, and some cisplatin-sensitive ovarian cancers have been shown to have a disruption in the FA/BRCA DNA damage repair pathway (Taniguchi et al., 2003) . These observations led to hypotheses that this molecular defect may be in part responsible for the improved survival of BRCA1/2 mutation carriers with ovarian cancer compared to women with sporadic ovarian cancer (Cass et al., 2003) , as platinum-based agents are standard therapy in this disease. In contrast, other preclinical models suggest that intact BRCA1 is necessary for chemotherapeutic effects of paclitaxel and therefore BRCA1-null tumors may be relatively chemoresistant. An ongoing clinical trial of mutation carriers with metastatic breast cancer comparing carboplatin and docetaxel (led by the Breakthrough Breast Cancer Centre and Cancer Research UK) was designed to test this hypothesis and should provide information on the clinical applicability of this finding and may have implications for adjuvant therapy. Lakhani et al. (2005) have recently demonstrated that 67% of BRCA1-related breast cancers express epidermal growth factor receptor (EGFR) expression (identified by immunohistochemistry), as compared to 21% of sporadic breast cancer controls. Therefore, EGFR-targeted therapy may by of potential benefit in these women, a hypothesis that will require testing. Finally, Ashworth and colleagues have demonstrated that poly(ADPribose) polymerase (PARP) inhibitors cause marked chromosomal instability and apoptosis in BRCA1 and BRCA2 null cells (Farmer et al., 2005) , suggesting that these agents may be useful therapeutically in treating BRCA1/2 mutation carriers with cancer. A Phase I trial is underway testing this hypothesis. Thus while standard prognostic features should currently be used to decide treatment decisions, clinical trials examining the issues outlined may alter treatment choices in the future.
Summary
Women with BRCA1/2 mutations should undergo bilateral PO once childbearing is complete to significantly reduce breast and ovarian cancer risk. Short-term use of HRT following oophorectomy appears safe and makes oophorectomy a more acceptable option to most patients. Women with mutations should be presented with options of PM vs frequent, high-resolution screening and chemoprevention. If the latter is chosen, we recommend alternating MRI and mammographic screening every 6 months. Until further information is available, HRT should be weaned off by age 45-50 years, and women then offered tamoxifen or enrollment on a chemoprevention study. At the current time, management of breast cancer in a known mutation carrier does not significantly differ from management of sporadic breast cancer, although novel approaches such as the use of PARP inhibitors to treat BRCA1/2-associated breast cancer may soon change this approach.
